Main image

Help women with fibromyalgia by supporting research

$3,793 of $20,000 goal
Given by 55 generous donors in over a year

Your donation will fund research exploring the role of the gut microbiome in symptoms & digestive problems in NZ women with fibromyalgia.

Auckland

Fibromyalgia is a chronic pain condition, poorly understood and difficult to treat.

The majority of sufferers are women. They live with constant pain, fatigue, headaches, digestive problems, sleep disturbances and more. It restricts their ability to function normally on many different levels.

This invisible condition has no obvious disability nor apparent cause, therefore patient experiences are often dismissed. Treatment options are limited and include pain killers, antidepressants and anticonvulsant drugs. No treatment is fully effective and many have to live with the symptoms their entire lives.

Studies have found that patients have AT LEAST one digestive problem, but how these relate to their symptoms is unclear. Often a patient’s symptoms change in relation with digestive function, but no-one knows why.

This research project aims to uncover more about this illness, which may provide information to help guide potential new treatments that target the digestive system and its microbiome to improve symptoms and quality of life in people living with fibromyalgia.

Our aim is to investigate whether gut bacteria are connected to other health problems, such as headaches, fatigue, sleep problems and digestive complaints, as well as other symptoms of fibromyalgia in New Zealand women. The suite of tests includes:

Stool microbiome (shotgun metagenomics),

Breath tests x3 (lactulose, glucose & fructose challenges),

Oral microbiome (shotgun - on those with elevated baseline breath gases),

Blood (RNA, BGL, electrolytes, FORT/FORD test),

Environmental mould (house),

Comprehensive questionnaires, and

Urine for Intestinal permeability (aka "leaky gut")

For more information visit the study website; https://www.theFidgitStudy.com

Sharon Erdrich's involvement (page creator)

I am co-ordinating the research project.

Use of funds

Your contribution will help pay for testing for intestinal hyperpermeability (also known as leaky gut). The cost of this is $130 per person - we plan to recruit 100 women for this study. With extra money, we can check other markers in the urine as well.

Read more

Latest update

RECRUITMENT IS COMPLETE  19 August 2022

Hello all FIDGIT study supporters. It has been incredible, just how willing women in New Zealand with fibromyalgia have been to get involved in the study - they have come from far and wide, and now we have reached our goal.

As of today, 109 women with fibromyalgia have enrolled in the study and 55 healthy controls have given generously of their time to participate.

Thank you so much for being a financial contributor. While we have not reached our fund-raising target, your support helps to cover at least some of the costs associated with recruitment, sample collection and equipment expenses. Thank you so much.

This fund-raising page is expiring late on Sunday. So if there is any way you can share the link as soon as possible, I would be very thankful.

Thanks so much.

Kind regards

Sharon

------------------------------

Sharon Erdrich (MHSc, PhD Cand.)

Based in Auckland, NZ

M: +64272393003

School of Pharmacy.

University of Sydney

sharon.erdrich@sydney.edu.au

Share this update

Read 14 more updates

Read more

Latest donations

Christina
Christina on 27 Jul 2022
$100
Douglas
Douglas on 22 Jul 2022
$5
Liz
Liz on 13 Jul 2022
$200
Renee
Renee on 12 Jul 2022
Best of luck with this study! I cannot wait to see the outcome!
$25
Trina
Trina on 07 Jul 2022
$20

Who's involved?

Sharon Erdrich's avatar
Created by, and paying to a verified bank account of, Sharon Erdrich on behalf of Women with fibromyalgia
Page Moderated
The page has been checked by our team to make sure it complies with our terms and conditions.

Gallery

Any concerns?

Report this page
This campaign started on 21 May 2021 and ended on 21 Aug 2022.